Compare MBUU & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | SLDB |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 498.6M |
| IPO Year | 2013 | 2017 |
| Metric | MBUU | SLDB |
|---|---|---|
| Price | $26.04 | $6.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $32.43 | $14.70 |
| AVG Volume (30 Days) | 256.1K | ★ 1.1M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | 36.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $807,561,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.07 | $2.45 |
| 52 Week High | $39.65 | $7.37 |
| Indicator | MBUU | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 57.46 |
| Support Level | $24.07 | $5.08 |
| Resistance Level | $34.22 | $7.05 |
| Average True Range (ATR) | 1.38 | 0.47 |
| MACD | -0.48 | 0.00 |
| Stochastic Oscillator | 4.23 | 94.74 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.